Leflunomide for rheumatoid arthritis and other rheumatological diseases (Adults)

It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility rests between Consultants and General Practitioners (GPs). This guideline reinforces the basic premise that:

When clinical and/or prescribing responsibility for a patient is transferred from hospital to GP, the GP should have full confidence to prescribe the necessary medicines. Therefore, it is essential that a transfer of care involving medicines that a GP would not normally be familiar with, should not take place without the “sharing of information with the individual GP and their mutual agreement to the transfer of care.”

These are not rigid guidelines. On occasions, Consultants and GPs may agree to work outside of this guidance. As always, the doctor who prescribes the medication has the clinical responsibility for the drug and the consequences of its use.

### Indications:
Leflunomide is used for the management of moderate to severe active rheumatoid arthritis and active psoriatic arthritis.

### Dosage and administration:
- **Rheumatoid arthritis:** 10mg or 20mg orally once daily when monotherapy is used.
- **Psoriatic arthritis:** 20mg once daily

Leflunomide may be taken with or without food.

The therapeutic response normally starts after 4-6 weeks and may improve further up to 4-6 months.

### Additional Information
- Recent or concurrent treatment with other hepatotoxic or haematotoxic DMARDs such as methotrexate may result in an increased risk of serious adverse reactions.
- The active metabolite of leflunomide has a half life of one to four weeks. If rapid clearance from the body is required (e.g. in the case of severe side effects), a washout procedure using colestyramine or activated powdered charcoal for 11 days should be used.
- Effective contraception is essential during treatment and for at least 2 years after treatment in women of childbearing potential. Male patients should also be aware of the possible male-mediated foetal toxicity and reliable contraception during treatment should be guaranteed and for at least 3 months after treatment.
- If a woman becomes pregnant they should be informed to contact their specialist or GP immediately to discuss the risks of leflunomide to the fetus.

### Monitoring requirements:
#### Before treatment:
- Full blood count (FBC)
- LFTs particularly alanine aminotransferase (ALT)
- Blood pressure (BP): If > 140/90mmHg on 2 consecutive readings 2 weeks apart then treat hypertension before commencing the drug.
- U/Es and creatinine

#### During treatment:
- FBC, LFTs, U/Es and creatinine weekly for the first month then monthly thereafter if stable
- BP should be checked at each monitoring visit - maintain ≤ 140/90mmHg.
- Annual fasting lipids (HDL, Cholesterol, HDL/Cholesterol ratio)
- ESR monthly for disease monitoring purposes

### Responsibility for monitoring rests with the GP
Action to be taken if abnormal results/adverse effects:

- **WBC < 3.5 x 10^9/l**
  - Check neutrophil count

- **Neutrophils < 2.0 x 10^9/l**
  - Monitor weekly. If it falls below 1.5 x 10^9/l STOP DRUG and contact helpline.

- **Platelets < 150 x 10^9/l**
  - Monitor weekly. If it drops below 100 x 10^9/l contact helpline.

- **3 fold rise in ALT/AST**
  - Monitor weekly. If ALT continues to rise, contact helpline.

- **Raised blood pressure**
  - If <140/90mmHg and persistently raised (more than 2 occasions), active management is required and contact helpline

- **Rash – mild**
  - Reduce to 10mg if necessary and observe

- **Rash - severe**
  - STOP DRUG and contact helpline for advice

- **Diarrhoea / nausea**
  - Assess severity, consider symptomatic treatment e.g. anti-diarrhoeal / anti-emetic
  - Usually does not require discontinuation of therapy. Dose reduction (where possible) may be considered

Please note that in addition to absolute values for haematological indices, a rapid fall or a consistent downward trend in any value should prompt caution and extra vigilance.

Contraindications:

- Hypersensitivity to the active substance (especially previous Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme) or to any of the excipients

- Avoid in hepatic impairment- active metabolite may accumulate

- Severe immunodeficiency status eg AIDS

- Serious infections

- Significantly impaired bone marrow function due to causes other than rheumatoid or psoriatic arthritis

- Avoid in moderate to severe renal insufficiency (CKD stages 3, 4 and 5 with a GFR less than 60ml/minute).

- Severe hypoproteinaemia eg in nephrotic syndrome

- Women who are pregnant, breast feeding or are of childbearing potential but not using reliable contraception.

- Live vaccines are contra-indicated in patients receiving leflunomide on theoretical grounds.

Drug interactions:

- Concurrent use of methotrexate increases the risk of hepatotoxicity and haematotoxicity.

Cautions:

- Renal impairment. Impaired bone marrow function, including anaemia, leucopenia or thrombocytopenia

- Recent treatment with other hepatotoxic or myelotoxic DMARDs.

- History of tuberculosis

Adverse Effects

Common: GI, including nausea, diarrhoea, vomiting and abdominal pain. Oral mucosal disorders.

Raised blood pressure.

Headache, paraesthesia, dizziness. Skin disorders such as alopecia, eczema, rash. Increased CPK.

Tenosynovitis.

Blood disorders: leucopenia (common), anaemia, thrombocytopenia (less common), agranulocytosis, pancytopenia (rare)

Rare: Severe infections, hepatitis and jaundice.
Specialist responsibilities:
- Confirm the diagnosis of rheumatoid arthritis
- Discuss with the patient the benefits and side effects of treatment with leflunomide
- If the patient is a woman of child bearing potential or male – ensure that they are aware of the importance of effective contraception and the need to discuss with their consultant if they wish to become pregnant
- Ensure that the patient understands and accepts their responsibilities (see section below)
- Seek consent for treatment and document in the patient’s notes.
- Ensure baseline monitoring of full blood count and biochemical profile.
- Discuss how the patient / carer can be aware of possible signs of leflunomide toxicity or intolerance
- Provide written instruction to the GP for initiation and escalation of leflunomide.
- Provide the patient with a shared care booklet and enter the blood results into the booklet.
- Review the patient at the intervals specified below to monitor the patient’s disease activity, the efficacy of the treatment and the ability to tolerate it, and consider whether continuation of treatment is appropriate.
- Discontinue if no response or patient has a significant adverse effect.
- Promptly communicate with the GP via a clinic letter any changes in treatment, results of monitoring undertaken, and assessment of adverse events. The clinic letter should clearly state if the dose has remained the same or if a dose adjustment had been made – specifically highlighting the new dose in comparison with the preceding one.
- Advise GPs when to stop treatment.
- Provide clear arrangements for back-up, advice and support.
- Report serious adverse events to the Committee on Safety of Medicines (CSM).

GP's responsibilities:
- Initial referral to Consultant Rheumatologist raising the possibility of rheumatological disease
- Provide the patient with monthly repeat prescriptions of medication following written instructions for initiation and escalation by the specialist. The patient should allow at least 48 hours for the prescription from the GP to be generated.
- Continue monitoring as outlined on the first page and document the results in the shared care booklet.
- Ensure patient’s shared care booklet and practice computer system are updated with any dose changes.
- Refer promptly to the specialist if there is a change in the patient’s status or concerns regarding compliance. In most cases, do not stop treatment without discussion with the Rheumatology Helpline.
- If patient fails to attend more than 2 monitoring visits it is not safe to continue treatment – contact the Rheumatology Helpline for advice.
- Report serious adverse events to the specialist and CSM.
- Administer Pneumococcal Vaccine/ Pneumovax® II and annual influenza vaccines.
- Consider passive immunisation with Varicella zoster immunoglobulin in non-immune patients exposed to chicken pox or shingles.

Patient responsibilities:
- Read the written patient information provided about the drug and have a clear understanding of the risks / benefits of oral leflunomide treatment.
- Attend for blood tests.
- Limit intake of alcohol to the national safe weekly limits
- Report any adverse effects to their GP and/or specialist whilst treated with leflunomide.
- Take monitoring booklet every time the patient sees the GP, has a hospital appointment or visits the pharmacist.
<table>
<thead>
<tr>
<th>Secondary care review: During initiation:</th>
<th>4 – 6 weekly until controlled</th>
</tr>
</thead>
<tbody>
<tr>
<td>Once disease controlled:</td>
<td>Annual review by consultant</td>
</tr>
<tr>
<td>Availability: 10mg tablet: 30 = £44.51</td>
<td>20mg tablet: 30 = £53.29</td>
</tr>
</tbody>
</table>

*Prices from November 2011 Drug Tariff*

<table>
<thead>
<tr>
<th>Back up advice and support:</th>
<th>Telephone:</th>
<th>0151 604 7505</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatology Helpline</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Written By:                             | Fiona Hughes, Lead Pharmacist, Rheumatology, Wirral University Teaching Hospital NHS Trust (WUTH) Dr Yee Ho Chiu, Consultant Rheumatologist, WUTH Dr Mano George, Consultant Rheumatologist, WUTH |
|-----------------------------------------|------------|---------------|
| Rachael Pugh, Clinical Effectiveness Pharmacist, Medicines Management Team, NHS Wirral |            |               |

Leflunomide for rheumatoid arthritis and other rheumatological diseases (Adult) – Shared Care Guideline. Version 1
Principal author: Rachael Pugh (PCT)
Approved by Wirral Drug and Therapeutics Committee: November 2011  Review date: November 2014